(Q36682388)

English

Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction

scientific article published on 12 December 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

1 reference

Europe PubMed Central

Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

neoadjuvant chemotherapy

1 reference

based on heuristic

inferred from title

4

object named as

Dennis S Chi

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

author name string

Robert E Bristow

1

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Eric L Eisenhauer

2

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Antonio Santillan

3

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

language of work or name

0 references

publication date

12 December 2006

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

104

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

480-490

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Identification of prognostic factors in advanced epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Interval debulking surgery in advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

The potential role of neoadjuvant chemotherapy in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Feasibility and outcome of complete secondary tumor resection for patients with advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Intervention debulking surgery in advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Secondary surgical cytoreduction for advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Factors associated with cytoreducibility among women with ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Predictive factors for irresectability in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Predictors of suboptimal surgical cytoreduction in women treated with initial cytoreductive surgery for advanced stage epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Diagnostic open laparoscopy in the management of advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

The role of induction chemotherapy in inoperable ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: Survival benefit and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Aggressive surgical effort and improved survival in advanced-stage ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Discordance between beliefs and recommendations of gynecologic oncologists in ovarian cancer management

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Primary chemotherapy and adjuvant tumor debulking in the management of advanced-stage epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Can pre-operative computed tomography predict resectability of ovarian carcinoma at primary laparotomy?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Advanced epithelial ovarian carcinoma: Long-term survival experience at the community hospital

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Management of ovarian cancer: referral to a multidisciplinary team matters

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

The impact of subspecialty training on the management of advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Interval debulking surgery: an alternative for primary surgical debulking?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.11.002

7 January 2021

Identifiers

10.1016/J.YGYNO.2006.11.002

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36682388&oldid=1646233762"